amiselimod vs Ponesimod

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline

amiselimod

Developed by Bausch Health under a licence from Tanabe Pharma Corporation

Phase 2 in Ulcerative ColitisSmall molecule (oral S1P receptor modulator)
Reliable signal

NCT04857112 · Phase 2 · completed

This trial randomly assigned 322 people with ulcerative colitis to one of two amiselimod doses or placebo, with participants and investigators unaware of assignment. The primary measure was change in the modified Mayo Score, which combines the appearance of the bowel lining at endoscopy with clinical disease activity. Scores fell by 2.3 points on amiselimod against 1.6 points on placebo (p=0.002).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Change from Baseline in the modified Mayo Score at Day 85 (Baseline to Day 85): Change from baseline in modified Mayo Score at Day 85: amiselimod -2.3 vs placebo -1.6 (p=0.002) (met)

Result source: NCT04857112

Ponesimod

Marketed by Vanda Pharmaceuticals and partners

Phase 3 in Ulcerative Colitissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2029 · NCT07686081 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointamiselimodPonesimod
Clinical remission (induction)—Not reported—Trial running · NCT07686081
Clinical remission (maintenance)—Not reported—Trial running · NCT07686081
Clinical response (induction)—Not reported—Trial running · NCT07686081
Endoscopic improvement (induction)—Not reported—Trial running · NCT07686081
Corticosteroid-free remission (maintenance)—Not reported—Trial running · NCT07686081

Clinical remission (induction)

amiselimod
—Not reported
Ponesimod
—Trial running · NCT07686081

Clinical remission (maintenance)

amiselimod
—Not reported
Ponesimod
—Trial running · NCT07686081

Clinical response (induction)

amiselimod
—Not reported
Ponesimod
—Trial running · NCT07686081

Endoscopic improvement (induction)

amiselimod
—Not reported
Ponesimod
—Trial running · NCT07686081

Corticosteroid-free remission (maintenance)

amiselimod
—Not reported
Ponesimod
—Trial running · NCT07686081
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Ponesimod: no structured comparison results are available for Ulcerative Colitis.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

amiselimod

Mayo 9 -2.3 vs -1.6 placebo score @ 12.142857wk
absolute change · score
NCT04857112 · Phase 2 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: amiselimod's landscape · Ponesimod's landscape